6.09

8.97% -0.60

After Hours: 6.19 0.10 +1.64%

Fulcrum Therapeutics Inc (FULC)

Overview News Price History Option Chain Financials Discussions Forecast

Fulcrum Therapeutics Inc stock is traded at $6.09, with a volume of 563.33K. It is down -8.97% in the last 24 hours and down -26.54% over the past month. Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Previous Close:

$6.69

Open:

$6.69

24h Volume:

563.33K

Relative Volume:

0.55

Market Cap:

$405.80M

Revenue:

$80.00M

Net Income/Loss:

$-76.12M

P/E Ratio:

-5.3118

EPS:

-1.1465

Net Cash Flow:

$-63.88M

1W Performance:

-13.00%

1M Performance:

-26.54%

6M Performance:

-37.41%

1Y Performance:

-11.48%

1-Day Range:

$6.08

$6.8099

1-Week Range:

$6.08

$7.32

52-Week Range:

$5.904

$15.74

Fulcrum Therapeutics Inc Stock (FULC) Company Profile

Name

Fulcrum Therapeutics Inc

Sector

Healthcare (1109)

Industry

Biotechnology (612)

Phone

617-651-8851

Address

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Employee

Twitter

@fulcrumtx

Next Earnings Date

2026-04-27

Latest SEC Filings

FULC's Discussions on Twitter

Compare FULC vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FULC Fulcrum Therapeutics Inc	6.09	445.78M	80.00M	-76.12M	-63.88M	-1.1465
VRTX Vertex Pharmaceuticals Inc	436.58	110.90B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	629.68	73.20B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	776.26	49.71B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	286.27	38.32B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	144.37	30.97B	742.00K	-1.37B	-1.07B	-7.0731

Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-12-26	Initiated	JP Morgan	Overweight
Nov-24-25	Initiated	Truist	Buy
Jul-29-25	Upgrade	H.C. Wainwright	Neutral → Buy
May-23-25	Upgrade	Leerink Partners	Market Perform → Outperform
May-15-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Sep-13-24	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-12-24	Downgrade	BofA Securities	Neutral → Underperform
Sep-12-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-12-24	Downgrade	Leerink Partners	Outperform → Market Perform
Sep-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Sep-12-24	Downgrade	Stifel	Buy → Hold
Sep-09-24	Upgrade	BofA Securities	Underperform → Neutral
May-20-24	Initiated	Cantor Fitzgerald	Overweight
Mar-13-24	Initiated	RBC Capital Mkts	Outperform
Sep-25-23	Initiated	Goldman	Neutral
Aug-23-23	Upgrade	H.C. Wainwright	Neutral → Buy
Aug-22-23	Upgrade	Stifel	Hold → Buy
May-04-23	Downgrade	Goldman	Buy → Neutral
Mar-10-23	Downgrade	Credit Suisse	Outperform → Neutral
Mar-10-23	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-09-23	Downgrade	Stifel	Buy → Hold
Feb-28-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-24-23	Downgrade	BofA Securities	Neutral → Underperform
Nov-15-22	Initiated	Goldman	Buy
Mar-08-22	Initiated	Oppenheimer	Outperform
Mar-03-22	Upgrade	BofA Securities	Underperform → Neutral
Aug-11-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Apr-26-21	Resumed	Credit Suisse	Outperform
Mar-22-21	Initiated	Credit Suisse	Outperform
Mar-02-21	Initiated	Stifel	Buy
Oct-16-20	Initiated	Piper Sandler	Overweight
Aug-12-20	Downgrade	BofA Securities	Neutral → Underperform
Aug-12-20	Reiterated	H.C. Wainwright	Buy
Aug-12-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-19-20	Downgrade	BofA/Merrill	Buy → Neutral
Jun-17-20	Initiated	BTIG Research	Buy
Oct-03-19	Initiated	H.C. Wainwright	Buy
Aug-12-19	Initiated	BofA/Merrill	Buy

View All

Fulcrum Therapeutics Inc Stock (FULC) Latest News

May 17, 2026

Fulcrum Therapeutics shares climb after Q1 earnings outperform expectations - MSN

May 17, 2026

Fulcrum Therapeutics, Inc.Common Stock (NQ: FULC - FinancialContent

May 17, 2026

May 15, 2026

Nantahala Capital files: 3,050,040 shares (4.58%) in THERAPEUTICS, INC. (FULC) - Stock Titan

May 15, 2026

Fulcrum Therapeutics (FULC) amendment shows 5.25M-share, 7.9% position - Stock Titan

May 15, 2026

May 14, 2026

Fulcrum Therapeutics (FULC) Holds $$7.25 — Direction Awaited 2026-05-14Debt Free Stocks - newser.com

May 14, 2026

May 11, 2026

Bank of America Securities Keeps Their Sell Rating on Fulcrum Therapeutics (FULC) - The Globe and Mail

May 11, 2026

Truist Securities Initiates Coverage of Fulcrum Therapeutics (FULC) with Buy Recommendation - MSN

May 11, 2026

May 10, 2026

Fulcrum Therapeutics (FULC.US) is scheduled to release its earnings report before the market opens on April 27. - Moomoo

May 10, 2026

May 08, 2026

Fulcrum Therapeutics (FULC) narrows Q1 loss 18% more than expected despite zero revenue; shares rise 2%.Growth Phase - newser.com

May 08, 2026

Fulcrum Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

May 08, 2026

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 08, 2026

Two new Fulcrum hires get 55,500 stock options at $7.02 a share - Stock Titan

May 08, 2026

What metric defines Fulcrum Therapeutics (FULC) success this quarter | Fulcrum Therapeutics Beats EPS ForecastTrending Stock Ideas - newser.com

May 08, 2026

FULC SEC FilingsFulcrum Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan

May 08, 2026

May 07, 2026

FULC.O Technical Analysis & Stock Price Forecast - Intellectia AI

May 07, 2026

May 02, 2026

Fulcrum Therapeutics (NASDAQ:FULC) Rating Increased to Sell at Wall Street Zen - MarketBeat

May 02, 2026

May 01, 2026

Fulcrum Therapeutics (FULC) director receives 64,000 stock options at $8.08 strike price - Stock Titan

May 01, 2026

Fulcrum Therapeutics (NASDAQ: FULC) director files Form 3 with no shares owned - Stock Titan

May 01, 2026

Apr 30, 2026

[ARS] Fulcrum Therapeutics, Inc. SEC Filing - Stock Titan

Apr 30, 2026

Executive pay and auditor vote at Fulcrum Therapeutics (NASDAQ: FULC) - Stock Titan

Apr 30, 2026

HC Wainwright Issues Optimistic Estimate for FULC Earnings - MarketBeat

Apr 30, 2026

Apr 29, 2026

Facioscapulohumeral Muscular Dystrophy Market: Pharma Pipeline Fuels Rapid Expansion – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics - Barchart.com

Apr 29, 2026

Facioscapulohumeral Muscular Dystrophy Market: Pharma - openPR.com

Apr 29, 2026

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Apr 29, 2026

Apr 28, 2026

FULC Should I Buy - Intellectia AI

Apr 28, 2026

Fulcrum Therapeutics Shares Surge After Beating Q1 Earnings Estimates - HarianBasis.co

Apr 28, 2026

H.C. Wainwright Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Maintains Target Price $25 - Moomoo

Apr 28, 2026

A Quick Look at Today's Ratings for Fulcrum Therapeutics(FULC.US), With a Forecast Between $10 to $25 - Moomoo

Apr 28, 2026

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q1 2026 Earnings Call Transcript - Insider Monkey

Apr 28, 2026